Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 4/20 | 0.34 |
| ▸ | NOS3 | P29474 | 3/20 | 0.34 |
| ▸ | F12 | P00748 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 2/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 5/20 | 0.32 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | CBLB | Q13191 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23479477 | 0.80 | RXFP1 (0.41) | MAPT | |
| SCHEMBL23473998 | 0.77 | DHFR (0.50) | ADORA2AADORA2BADORA1MAPTNOS2 | |
| SCHEMBL23478506 | 0.73 | ADORA2A (0.40) | ADORA2AADORA2BADORA1MAPTNOS2 | |
| SCHEMBL23478375 | 0.68 | DHFR (0.32) | DHFR | |
| SCHEMBL27017056 | 0.67 | GPR3 (0.39) | MAPT | |
| SCHEMBL6704088 | 0.66 | DHFR (0.47) | ADORA2AADORA2BADORA1MAPTNOS2 | |
| SCHEMBL14327823 | 0.66 | RPS6KA5 (0.41) | ADORA2A | |
| SCHEMBL19531662 | 0.66 | KDM4E (0.39) | — | |
| SCHEMBL23478504 | 0.66 | ATM (0.41) | MAPT | |
| SCHEMBL15519665 | 0.65 | RXFP1 (0.36) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ADORA2A 3908/4885ADORA2B 3963/4885ADORA1 4817/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ADORA2A 3862/4885ADORA2B 3940/4885ADORA1 4810/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ADORA2A 3862/4885ADORA2B 3940/4885ADORA1 4810/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | ADORA2A 3862/4885ADORA2B 3940/4885ADORA1 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.